Alpha Tau Medical (DRTS) Fundamental Analysis: Revenue, Earnings & Valuation

0.66 / 10

Underperform

Fundamental assessment rates the stock as Underperform with a 0.7/10 quality score. Revenue‑to‑market and cash‑up metrics are modestly positive, while profit‑to‑market, net‑income‑revenue and margins are negative, indicating poor profitability and high risk.

Analysis Checks(2/10)

Revenue-MV

Value-0.11

Score3/3

Weight-12.95%

1M Return3.85%

Net cash flow from operating activities / Operating revenue (%)

Value-982.50

Score0/3

Weight21.95%

1M Return-9.58%

Profit-MV

Value0.66

Score1/3

Weight7.79%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight6.97%

1M Return-2.58%

Net profit margin (%)

Value-1264.47

Score0/3

Weight21.48%

1M Return-9.31%

Cash-UP

Value-0.15

Score3/3

Weight-8.18%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value-0.93

Score1/3

Weight10.24%

1M Return-4.08%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight21.02%

1M Return-9.03%

Asset-MV

Value-0.55

Score0/3

Weight10.22%

1M Return-3.70%

Net profit / Total operating revenue (%)

Value-654.10

Score0/3

Weight21.48%

1M Return-9.31%

Is DRTS fundamentally strong?

DRTS scores 0.66/10 on fundamentals and holds a Premium valuation at present. Backed by its -61.00% ROE, 0.00% net margin, -14.29 P/E ratio, 7.90 P/B ratio, and -17.78% earnings growth, these metrics solidify its Underperform investment rating.